Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early-intensified pharmacological treatment versus treatment as usual for bipolar depression after first-line treatment failure
ACTRN12625000328471Phase 3Not yet recruiting
- Sponsor
- University of Adelaide
- Start
- Apr 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of quetiapine, lithium, valproic acid, escitalopram, sertraline and 3 more in bipolar disorder (BD) (2 arms), sponsored by University of Adelaide. Primary endpoint: Change in depressive symptom severity. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
quetiapinelithiumvalproic acidescitalopramsertraline
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on ACTRN12625000328471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000328471.